WO2005097813A1 - Isomeres complexes de platine demethyl-cantharidine et leur utilisation - Google Patents
Isomeres complexes de platine demethyl-cantharidine et leur utilisation Download PDFInfo
- Publication number
- WO2005097813A1 WO2005097813A1 PCT/CN2005/000463 CN2005000463W WO2005097813A1 WO 2005097813 A1 WO2005097813 A1 WO 2005097813A1 CN 2005000463 W CN2005000463 W CN 2005000463W WO 2005097813 A1 WO2005097813 A1 WO 2005097813A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- trans
- isomer
- cancer
- structural formula
- platinum complex
- Prior art date
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title claims abstract description 126
- 229910052697 platinum Inorganic materials 0.000 title claims abstract description 61
- JAABVEXCGCXWRR-FBXFSONDSA-N rel-norcantharidin Chemical compound C1C[C@H]2[C@@H]3C(=O)OC(=O)[C@@H]3[C@@H]1O2 JAABVEXCGCXWRR-FBXFSONDSA-N 0.000 title claims abstract description 49
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 30
- 229960004562 carboplatin Drugs 0.000 claims abstract description 20
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract description 20
- 229960004316 cisplatin Drugs 0.000 claims abstract description 20
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims abstract description 16
- 229960001756 oxaliplatin Drugs 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 31
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 claims description 19
- 201000007270 liver cancer Diseases 0.000 claims description 13
- 208000014018 liver neoplasm Diseases 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 206010009944 Colon cancer Diseases 0.000 claims description 11
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 11
- 206010025323 Lymphomas Diseases 0.000 claims description 11
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 11
- 206010033128 Ovarian cancer Diseases 0.000 claims description 11
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 11
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 11
- 201000010881 cervical cancer Diseases 0.000 claims description 11
- -1 demethylcantharidin platinum compound Chemical class 0.000 claims description 11
- 208000032839 leukemia Diseases 0.000 claims description 11
- 201000005202 lung cancer Diseases 0.000 claims description 11
- 208000020816 lung neoplasm Diseases 0.000 claims description 11
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 10
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 10
- 208000029742 colonic neoplasm Diseases 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 230000004614 tumor growth Effects 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 241000239218 Limulus Species 0.000 claims 1
- 230000012010 growth Effects 0.000 abstract description 2
- 190000008236 carboplatin Chemical compound 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- YMHQVDAATAEZLO-UHFFFAOYSA-N cyclohexane-1,1-diamine Chemical compound NC1(N)CCCCC1 YMHQVDAATAEZLO-UHFFFAOYSA-N 0.000 description 13
- 239000002609 medium Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- IXLVUUFUDRJUSL-RPBOFIJWSA-N 5-[[4-(3-acetamidophenyl)phenyl]methyl]-n-[(1s,2r)-2-phenylcyclopropyl]-1,3-oxazole-4-carboxamide Chemical compound CC(=O)NC1=CC=CC(C=2C=CC(CC3=C(N=CO3)C(=O)N[C@@H]3[C@H](C3)C=3C=CC=CC=3)=CC=2)=C1 IXLVUUFUDRJUSL-RPBOFIJWSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 description 3
- 229940095758 cantharidin Drugs 0.000 description 3
- 229930008397 cantharidin Natural products 0.000 description 3
- DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002983 circular dichroism Methods 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000005918 in vitro anti-tumor Effects 0.000 description 3
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 3
- 150000002823 nitrates Chemical class 0.000 description 3
- 239000003961 penetration enhancing agent Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- SSJXIUAHEKJCMH-LWOQYNTDSA-N (1r)-cyclohexane-1,2-diamine Chemical compound NC1CCCC[C@H]1N SSJXIUAHEKJCMH-LWOQYNTDSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001142 circular dichroism spectrum Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 150000003057 platinum Chemical class 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- 238000012573 2D experiment Methods 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 101710134784 Agnoprotein Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001481669 Meloidae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001644 anti-hepatocarcinoma Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003058 platinum compounds Chemical group 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Definitions
- Figure 3 is a circular dichroism spectrum of S, S-DMC platinum complex (0.25mg / ml), showing its reproducibility
- Figure 4 is a circular dichroism spectrum of DMC (0.1 mg / ml), showing that it has no optical activity. detailed description
- the above tumor cells include tumor cells sensitive to and resistant to cisplatin, carboplatin, or oxaliplatin, and the tumor cells are derived from lung cancer, liver cancer, breast cancer, colon cancer, ovarian cancer, and cervix Cancer, leukemia, lymphoma or nasopharyngeal cancer. ⁇
- An organic solvent such as tetrahydrofuran (THF) is used as a solvent to react furan with maleic anhydride to prepare an intermediate.
- a Pd-C catalyst is added. The reaction mixture was refluxed and hydrogen gas was passed through to prepare a DMC ligand.
- step 2 To the Pt (II) nitrate derivative obtained in step 2 orally, the DMC ligand obtained in step 1 was added, and then NaOH was added to prepare a DMC platinum complex.
- trans-R, R-DMC platinum complex and trans A-S ⁇ -DMC platinum complex are 0.25mg / ml;
- Trans-R, R-1,2-diaminocyclohexane and trans-S, S-1,2-diaminocyclohexane are 1mg / lml;
- Hu -7 resistance 25.64 ⁇ 3.50 (2) 175.60 ⁇ 53.95 (1) 26.95 ⁇ 3.03 (2) 17.06 ⁇ 0.77 (1) 5.99 ⁇ 0.52 (1) 16.22 ⁇ 2.60 (1) 26.93 ⁇ 6.14 (1)
- trans-R, R (-) isomer is about 10 times more potent against HCT-116 and HT-29 cell lines than cis-4.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007506641A JP2007532494A (ja) | 2004-04-08 | 2005-04-08 | デメチルカンタリジン白金錯体の立体異性体及びその使用 |
EP05741689A EP1749831A4 (en) | 2004-04-08 | 2005-04-08 | COMPLEX ISOMERS OF PLATINUM DEMETHYL-CANTHARIDINE AND THEIR USE |
US11/578,002 US20070293467A1 (en) | 2004-04-08 | 2005-04-08 | Demethyl-Cantharidin Platinum Complex Isomers and Their Use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200410033701.1 | 2004-04-08 | ||
CNA2004100337011A CN1680384A (zh) | 2004-04-08 | 2004-04-08 | 去甲基斑蟊素铂配合物及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005097813A1 true WO2005097813A1 (fr) | 2005-10-20 |
Family
ID=35067191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2005/000463 WO2005097813A1 (fr) | 2004-04-08 | 2005-04-08 | Isomeres complexes de platine demethyl-cantharidine et leur utilisation |
Country Status (5)
Country | Link |
---|---|
US (1) | US20070293467A1 (zh) |
EP (1) | EP1749831A4 (zh) |
JP (1) | JP2007532494A (zh) |
CN (1) | CN1680384A (zh) |
WO (1) | WO2005097813A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101367850B (zh) * | 2008-10-15 | 2011-08-10 | 苏州大学 | 去甲基斑蟊素衍生物及其合成方法 |
CN102863474A (zh) * | 2011-07-09 | 2013-01-09 | 陈小平 | 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用 |
WO2018024172A1 (en) * | 2016-08-05 | 2018-02-08 | The University Of Hong Kong | Platinum complexes and methods of use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1120544A (zh) * | 1995-03-29 | 1996-04-17 | 邹娟 | 新的抗肿瘤铂络合物 |
CN1580054A (zh) * | 2003-07-31 | 2005-02-16 | 中国人民解放军军事医学科学院毒物药物研究所 | 五元硫杂环类化合物及其用于制备治疗和预防肥胖相关疾病的药物的用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1068002C (zh) * | 1997-04-30 | 2001-07-04 | 中国科学院大连化学物理研究所 | 铂抗癌药物及合成 |
US20040152766A1 (en) * | 2001-05-31 | 2004-08-05 | Au-Yeung Steven C.F. | Composition comprising demethylcantharidin in combination with platinum-containing anticancer agents and use thereof |
-
2004
- 2004-04-08 CN CNA2004100337011A patent/CN1680384A/zh active Pending
-
2005
- 2005-04-08 EP EP05741689A patent/EP1749831A4/en not_active Withdrawn
- 2005-04-08 WO PCT/CN2005/000463 patent/WO2005097813A1/zh active Application Filing
- 2005-04-08 US US11/578,002 patent/US20070293467A1/en not_active Abandoned
- 2005-04-08 JP JP2007506641A patent/JP2007532494A/ja not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1120544A (zh) * | 1995-03-29 | 1996-04-17 | 邹娟 | 新的抗肿瘤铂络合物 |
CN1580054A (zh) * | 2003-07-31 | 2005-02-16 | 中国人民解放军军事医学科学院毒物药物研究所 | 五元硫杂环类化合物及其用于制备治疗和预防肥胖相关疾病的药物的用途 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1749831A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP1749831A4 (en) | 2007-12-12 |
US20070293467A1 (en) | 2007-12-20 |
JP2007532494A (ja) | 2007-11-15 |
EP1749831A1 (en) | 2007-02-07 |
CN1680384A (zh) | 2005-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018075993A1 (en) | Compounds and methods to sensitize cancer cells to tyrosine kinase inhibitors | |
Bekhit et al. | Synthesis, characterization and cytotoxicity evaluation of some new platinum (II) complexes of tetrazolo [1, 5-a] quinolines | |
CA2635318A1 (en) | Triterpenequinone and triterpenephenol derivatives and their application for the treatment of tumors and parasitic diseases | |
US10273257B2 (en) | Cancer cell-containing composition | |
US6057303A (en) | Highly lipophilic Camptothecin derivatives | |
Baul et al. | New dibutyltin (iv) ladders: Syntheses, structures and, optimization and evaluation of cytotoxic potential employing a375 (melanoma) and hct116 (colon carcinoma) cell lines in vitro | |
WO2005097813A1 (fr) | Isomeres complexes de platine demethyl-cantharidine et leur utilisation | |
Galanski et al. | Is reduction required for antitumour activity of platinum (IV) compounds? Characterisation of a platinum (IV)–nucleotide adduct [enPt (OCOCH3) 3 (5′-GMP)] by NMR spectroscopy and ESI-MS | |
CN114907417A (zh) | 一类含有青蒿琥酯及非甾体抗炎药的四价铂三元配合物及其制备方法与应用 | |
EP3252039B1 (en) | Compound containing indoleacetic acid core structure and use thereof | |
CN111196922B (zh) | pH敏感型β-咔啉衍生物荧光探针在肿瘤荧光成像中的应用 | |
Yang et al. | Enantioselective semisynthesis of novel cephalotaxine esters with potent antineoplastic activities against leukemia | |
US6110907A (en) | Synthesis of platinum complexes and uses thereof | |
CN114409712B (zh) | 一种含大麻二酚Pt(Ⅳ)配合物及其制备方法和应用 | |
US10494391B2 (en) | Two-component anti-cancer composition | |
CN114853802B (zh) | 一种谷内酯衍生物及其制备方法、药物组合物和应用 | |
US11571430B2 (en) | Platinum(II) ammine selenourea complexes and methods of treating cancer | |
CN110590852A (zh) | 一种具有抗肿瘤活性的铂配合物及其制备方法 | |
CN114853784A (zh) | 一种十字孢碱类化合物及其制备方法与应用 | |
CN102649810A (zh) | 喜树碱衍生物、其制备方法和用途 | |
JPH07138274A (ja) | Z軸上に脂溶性基を有する抗腫瘍性シクロヘキサンジアミン誘導体白金(iv)錯体 | |
FR2523978A1 (fr) | Nouvelle nitrosouree steroide a propriete oncostatique, procede pour sa preparation et son utilisation a titre de medicament |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007506641 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005741689 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005741689 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11578002 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 11578002 Country of ref document: US |